These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 19553086)
1. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086 [TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK; Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466 [TBL] [Abstract][Full Text] [Related]
4. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial. Crespo-Facorro B; Ortiz-García de la Foz V; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Vázquez-Barquero JL; Pérez-Iglesias R Schizophr Res; 2013 Jul; 147(2-3):375-82. PubMed ID: 23643328 [TBL] [Abstract][Full Text] [Related]
5. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914 [TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. McCue RE; Waheed R; Urcuyo L; Orendain G; Joseph MD; Charles R; Hasan SM Br J Psychiatry; 2006 Nov; 189():433-40. PubMed ID: 17077434 [TBL] [Abstract][Full Text] [Related]
7. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752 [TBL] [Abstract][Full Text] [Related]
8. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y; Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE; Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841 [TBL] [Abstract][Full Text] [Related]
10. The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. Hatta K; Takebayashi H; Sudo Y; Katayama S; Kasuya M; Shirai Y; Morikawa F; Nakase R; Nakamura M; Ito S; Kuga H; Nakamura M; Ohnuma T; Usui C; Nakamura H; Hirata T; Sawa Y; Psychiatry Res; 2013 Dec; 210(2):396-401. PubMed ID: 23919898 [TBL] [Abstract][Full Text] [Related]
11. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. Jensen JB; Kumra S; Leitten W; Oberstar J; Anjum A; White T; Wozniak J; Lee SS; Schulz SC J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):317-26. PubMed ID: 18759641 [TBL] [Abstract][Full Text] [Related]
12. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison. Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371 [TBL] [Abstract][Full Text] [Related]
13. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Hatta K; Otachi T; Sudo Y; Hayakawa T; Ashizawa Y; Takebayashi H; Hayashi N; Hamakawa H; Ito S; Nakase R; Usui C; Nakamura H; Hirata T; Sawa Y; Schizophr Res; 2011 May; 128(1-3):127-35. PubMed ID: 21420283 [TBL] [Abstract][Full Text] [Related]
14. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
15. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. Al-Dhaher Z; Kapoor S; Saito E; Krakower S; David L; Ake T; Kane JM; Correll CU; Carbon M J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):458-70. PubMed ID: 27093218 [TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Katona L; Czobor P; Bitter I Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Boter H; Peuskens J; Libiger J; Fleischhacker WW; Davidson M; Galderisi S; Kahn RS; Schizophr Res; 2009 Dec; 115(2-3):97-103. PubMed ID: 19819114 [TBL] [Abstract][Full Text] [Related]
18. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767 [TBL] [Abstract][Full Text] [Related]
19. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Soares-Weiser K; Béchard-Evans L; Lawson AH; Davis J; Ascher-Svanum H Eur Neuropsychopharmacol; 2013 Feb; 23(2):118-25. PubMed ID: 22633617 [TBL] [Abstract][Full Text] [Related]
20. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]